Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
Jump to navigation
Jump to search
m (table) |
|||
| Line 11: | Line 11: | ||
nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance AED | nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance AED | ||
<ref>(Davis et al 2008)</ref> | <ref>(Davis et al 2008)</ref> | ||
{| class="toccolours float-right taxobox pilze" style="font-size:80%;" cellpadding="3" cellspacing="3" | |||
| colspan="3" background-color:#000000;" | | |||
|- | |||
| colspan="3" style="text-align:center; font-size:120%; background-color:#32CD32;" | <font color="black"> | |||
'''Medicines''' | |||
|- | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|cellpadding="3" cellspacing="3" align="left" style="background:#99ff99" |'''type''' | |||
|[[,,,]] | |||
|[[,,,,]] | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''INN''' |||[[Generic]] | |||
|slow release | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''carbazepine''' |||[[normal]] | |||
|xr | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''lamotrigine''' |||[[normal]] | |||
|xr | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''levetiracetam''' ||[[normal]] | |||
|xr | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''oxcarbazepine''' ||[[...]] | |||
|xr | |||
|- style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''phenitoin''' ||[[...]] | |||
|xr | |||
|-style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''valproate''' || | |||
|colspan="3" | xr | |||
|-style="vertical-align:top; background:#ffffff;" | |||
|align="left" style="background:#99ff99"|'''topiramat''' || | |||
|colspan="3" | xr | |||
|- | |||
| colspan="3" style="text-align:center; font-size:120%; background-color:#32CD32;" | | |||
<font color="black"> '''AED''' | |||
|- | |||
|} | |||
==[[International League Against Epilepsy |ILAE]] Classification== | ==[[International League Against Epilepsy |ILAE]] Classification== | ||
| Line 20: | Line 62: | ||
[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population] | [http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population] | ||
[[Dravet's syndrome]] | [[Dravet's syndrome]] | ||
{{refs}} | {{refs}} | ||
[[nl:epilepsie]] | [[nl:epilepsie]] | ||
Revision as of 17:06, 25 July 2015
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO states 50 millions persons affect by epilepsy[2]
nonadherence appears to be associated with increased health care costs,nevertheless XR-medicine appears as strategy to overcome compliance AED [3]
|
Medicines | ||||
| type | ,,, | ,,,, | ||
| INN | Generic | slow release | ||
| carbazepine | normal | xr | ||
| lamotrigine | normal | xr | ||
| levetiracetam | normal | xr | ||
| oxcarbazepine | ... | xr | ||
| phenitoin | ... | xr | ||
| valproate | xr | |||
| topiramat | xr | |||
|
AED | ||||
ILAE Classification
[4] [5] A new perspective for Epileptic Disorders
Links
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population Dravet's syndrome
| References: |
|